HOME >> MEDICINE >> NEWS
Cancer drug is first to alleviate devastating scleroderma symptoms

BACKGROUND:
Scleroderma is a debilitating autoimmune disease that attacks the connective tissues and especially the lungs. Hardening of the skin is one of the most visible effects of the disease. Over 40 percent of patients will develop symptomatic lung problems the leading cause of death for scleroderma patients.

FINDINGS:
A new nationwide study headed by UCLA found that a drug used for cancer called cyclophosphamide, helped alleviate the serious effects of scleroderma on breathing, lung function, quality of life, functional disability and skin thickness. This is the first controlled clinical trial to show a positive treatment for scleroderma lung disease.

IMPACT:
Findings will help researchers develop new drug therapies and also better understand development of the disease. The next step is further research into use of cylophosphamide as well as other immunosuppressant drugs.

AUTHORS:
Drs. Donald Tashkin and Michael Roth, professors of pulmonary and critical care medicine; and Drs. Philip Clements and Daniel Furst, professors of rheumatology, David Geffen School of Medicine at UCLA.


'"/>

Contact: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-2270
University of California - Los Angeles
21-Jun-2006


Page: 1

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
10. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
11. Cancer-fighting foods, supplements explored in day-long symposium, March 25

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Dr. Barry ... Avenue Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic ... of the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Houston ... 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine European ... European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, clinicians, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Swirl: A Wine Tasting Event in New York City, with long-time partners The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Several leading Alzheimer,s disease experts will participate in ... 11 a.m. EST on December 6 in advance of ... Alzheimer,s Disease (CTAD). The program will include discussions on ... targets that address deficient glucose metabolism observed in Alzheimer,s ... another therapy targeting the amyloid hypothesis, now more than ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Florida Institute for the Commercialization of Public Research ... has finalized a funding agreement SegAna, LLC, an ... developed at University of Central Florida. The Florida ... research, and bridges early funding gaps for companies ...
(Date:12/5/2016)... , December 5, 2016 According to a ... modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application ... MarketsandMarkets, the market is projected to reach USD 779.8 Million by ... of 13.5% during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology:
Cached News: